-->

Tag: FDA-approved targeted therapies 2025

Home / FDA-approved targeted therapies 2025

Categories

Fam-trastuzumab deruxtecan-nxki is approved by the USFDA for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer

On January 27, 2025, the Food and Drug Administration sanctioned fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for unresectable or metastatic hormone receptor (HR)-positive, HER2-low...
fda-approved-targeted-therapies-2025

Datopotamab deruxtecan-dlnk is approved by the USFDA for unresectable or metastatic, HR-positive, HER2-negative breast cancer

On January 17, 2025, the Food and Drug Administration sanctioned datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-targeted antibody and topoisomerase inhibitor conjugate, for adu...
fda-approved-targeted-therapies-2025

Encorafenib with cetuximab and mFOLFOX6 is approved by the USFDA for metastatic colorectal cancer with a BRAF V600E mutation

On December 20, 2024, the Food and Drug Administration conferred accelerated approval for encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in conjunction with cetuximab and mF...
fda-approved-targeted-therapies-2025

Scan the code